Clinical Trials Logo

Clinical Trial Summary

Benign prostatic hyperplasia (BPH) is one of the most prevalent human diseases and a major cause of lower urinary tract symptoms (LUTS). Some men respond to current medical treatment (mainly α-1 adrenoreceptor antagonists and 5 α-reductase inhibitors), but a large proportion of patients continues to need a surgical procedure to treat resistant LUTS or even more serious complications of BPH, creating the emerging necessity for novel pharmacological therapies. Oxitriptan may have a possible positive effect on BPH associated symptoms with probably no impact in sexual function (which is a common side effect of the current drugs for BPH associated symptoms). Also, improvement in symptoms could be higher than that of current drugs used for this condition. This is a single-center parallel group, randomized clinical trial. The study will take place in Hospital de Braga (Urology department). Eligible patients will be randomized to receive tamsulosin 0.4mg (once a day, q.d.) or 5-HTP (5-hidroxitriptophan) 100mg (three times a day, t.i.d.), for 6 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05401032
Study type Interventional
Source Clinical Academic Center (2CA-Braga)
Contact
Status Not yet recruiting
Phase Phase 2
Start date June 2022
Completion date December 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02974751 - Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
Terminated NCT04398966 - Prostatic Artery Embolization vs Medication for Benign Prostatic Hyperplasia N/A
Completed NCT04029012 - Penthrox in Rezūm BPH Phase 4
Recruiting NCT03912558 - Pilot Study to Assess the Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in BPH Patients. N/A
Completed NCT00527488 - Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia. Phase 2
Recruiting NCT06323109 - US Imaging for the Assessment of LUTS
Completed NCT05628025 - Simulation-Based Enucleation Training: Initial Experience Using 3D-printed Organ Phantoms
Completed NCT00407329 - Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia N/A
Completed NCT00256399 - Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED) N/A
Terminated NCT03994263 - A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI N/A
Completed NCT03772808 - Effects of LycoComfort™ Supplementation on Symptoms Associated With Lower Urinary Tract Symptoms (LUTS) N/A
Completed NCT05818670 - Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study Phase 4
Withdrawn NCT02961114 - Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy Phase 1/Phase 2
Active, not recruiting NCT04198103 - Transperineal Laser Ablation for Percutaneous Treatment of Benign Prostatic Hyperplasia N/A
Completed NCT00696761 - The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients Phase 4
Completed NCT00199550 - Bipolar vs Monopolar Transurethral Resection of the Prostate (TURP) Phase 4
Completed NCT02702947 - Efficacy of Prunus Domestica Extract in BPH Phase 4
Completed NCT00154843 - A Clinical Study to Determine Factors Affecting Absorption and Serum Levels of Lycopene After Supplementation Phase 2
Completed NCT00037141 - Safety/Tolerability Study of Alcohol Injection for Treatment of BPH (Enlarged Prostate) Phase 1/Phase 2
Recruiting NCT05620784 - Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP Phase 3